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a b s t r a c t
Motor problems in Prader–Willi syndrome (PWS) are presumably related to abnormal body composition
and certain neuromuscular abnormalities. The authors reviewed the literature to evaluate the extent to
which body composition is affected and gathered all ﬁndings on neuromuscular functioning in PWS. A
systematic review was conducted in four databases (1956–2010). The methodological quality of each
included article was evaluated. Thirty-eight papers were included: body composition (9 studies), neuro-rader–Willi syndrome
ody composition
rowth hormone
uscle mass
ystematic review
muscular functioning (7) and growth hormone (GH) effect studies (23). Increased fat mass and decreased
lean body mass are characteristics of PWS. As a result, muscle mass is decreased by 25–37%, which might
explain partly the weakness and hypotonia. However, there are also structural and functional muscle
abnormalities, and cortical motor areas are hypo-excitable in PWS patients. Moreover, disuse as result of
decreased activity in PWS could also contribute. GH treatment positively inﬂuences body composition,
but does not normalize it. Training could prevent disuse and improves body composition. Therefore GH
treatment and training will probably enhance one another.
© 2010 Elsevier Ltd. Open access under the Elsevier OA license.
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. Introduction
Prader, Labhart, andWilli ﬁrst described Prader–Willi syndrome
PWS) in 1956 (Prader et al., 1956). PWS is a neurogenetic dis-
rder resulting from absent expression of the paternal region of
hromosome15q11-13. In about 70%of cases it is causedbyapater-
al deletion (Butler et al., 1986; Ledbetter et al., 1981), in about
5% of cases by maternal uniparental disomy (Holm et al., 1993;
ascari et al., 1992; Nicholls et al., 1989), and in 1–5% it is caused
y an imprinting center mutation or translocation (Cassidy, 1997;
aitoh et al., 1997). The estimated prevalence is 1 in 10,000–30,000
irths (Whittington et al., 2001). PWS is characterized by a wide
ariety of physical, cognitive, and behavioral defects. The most sig-
iﬁcant characteristics are hypotonia in infancy, hypogonadism,
besity, short stature, motor delay, cognitive deﬁcits, and mild
ysmorphic facial features (Cassidy, 1984; Holm et al., 1993). The
resence of symptoms is mostly age-dependent; not all symptoms
re expressed in all patients, and the severity of disabilities differs
etween patients. In this paperwe are particularly interested in the
ymptoms in PWS which contribute to their motor problems.
Motor performance in PWS is particularly affected in infancy.
n the majority of cases, newborns are severely hypotonic, inactive
nd sometimes almost motionless. After several weeks or months
he infants become more responsive and are capable of more
pontaneous movement, although they continue to suffer from
ypotonia,muscleweakness and as a result severely delayedmotor
evelopment (Aﬁﬁ and Zellweger, 1969; Cassidy, 1984; Eiholzer
t al., 2001, 2008; Festen et al., 2008a). Motor problems are still
resent in childhood and adulthood, and decreased activity in PWS
atients is reported (Butler et al., 2007; Davies and Joughin, 1993;
ill et al., 1990; Schoeller et al., 1988; Van Mil et al., 2000a). PWS
atients score well below the normal range on standardized motor
erformance tests (Carrel et al., 2002; Mullins and Vogl-Maier,
987), and they have an abnormal gait pattern (Vismara et al.,
007). The causes of hypotonia, muscle weakness, and motor prob-
ems in PWS patients are not clear; it is presumed however that
he contributing factors are the abnormal body composition in PWS
atients,withan increase in fatmass andadecrease inmusclemass,
nd possibly some degree of neuromuscular abnormality (Lewis,
000; Sone, 1994).
Abnormal body composition in PWS patients is thought to be
elated to hormonal deﬁciencies as a result of hypothalamic dys-. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 967
function (Burman et al., 2001; Eiholzer andWhitman, 2004; Swaab,
1997). Indeed several studies have foundanatomical and functional
abnormalities of the hypothalamus (Gabreëls et al., 1998; Iughetti
et al., 2008; Miller et al., 1996; Miller et al., 2008; Swaab et al.,
1995). Moreover, growth hormone (GH) (Eiholzer et al., 2000a)
and hormones of the thyroid (Butler et al., 2007; Festen et al.,
2007), gonads (Eiholzer et al., 2006; Muller, 1997), and adrenal
cortex (De Lind van Wijngaarden et al., 2008) are found to be
affected. The most signiﬁcant ﬁnding in relation to body composi-
tion in PWS patients is GH deﬁciency. GH deﬁciency presumably
leads to the short stature, decreased lean body mass, increased
fat mass, and decreased bone mineral density in PWS patients
(Eiholzer et al., 2000a). GH treatment leads not only to an increase
in height, but also to a decrease in fat mass and an increase in
lean body mass in PWS patients (Carrel et al., 1999, 2002, 2004;
Davies et al., 1998). In some GH studies it is presumed that GH
treatment could also have a positive effect on muscle strength,
motor development and/or performance, because GH positively
inﬂuences body composition (Carrel et al., 1999, 2004; Eiholzer
et al., 1998).
To evaluate the extent to which the body composition abnor-
malities in PWS may contribute to the motor problems, it is
necessary to gather insight into the severity of the abnormalities in
relation toage, aswell as theirprogressover time.Toourknowledge
there are no longitudinal studies that focus on body composition
in PWS. There are several cross-sectional studies but the results of
these studies have never been systematically reviewed.Wewanted
to perform a systematical literature study on body composition in
PWS to critically review the ﬁndings and obtain more insight into
the presumed relationship between body composition abnormal-
ities, hypotonia, muscle weakness, and motor problems in PWS.
Additionally it has been hypothesized that abnormalities in neu-
romuscular functioning could contribute to the motor problems in
PWS patients. Only three studies are frequently mentioned with
regard to this hypothesis (Aﬁﬁ and Zellweger, 1969; Civardi et al.,
2004; Sone, 1994). We wanted to know if there are more stud-
ies that focus on neuromuscular functioning in PWS and therefore
expanded our literature study to both topics. In this paper we
describe the ﬁndings of our systematic literature study regard-
ing body composition and neuromuscular functioning in PWS and
review the effects of GH treatment on body composition. The
methodological quality of all references included in this review
9 obehavioral Reviews 35 (2011) 956–969
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Table 1
Exclusion criteria.
Reason for exclusion Number of articles
excluded
Case report 15
Non-systematical review/opinion-based 12
Animal research 5
No abstract available 8
Syndrome different from PWS/not PWS speciﬁc 32
Different focus
Breathing/sleep 31
Behavior/cognition/language 15
Glucose metabolism/insulin/diabetic 15
Hyperphagia/diet/obesity 15
Fitness 14
Bone mineral density/scoliosis/hip
dysplasia/orthopedic
14
Genetic 12
Hormonal functioning 10
Visual perception 7
Anthropometric/craniofacial features 6
Cardiovascular disease 558 L. Reus et al. / Neuroscience and Bi
as assessed in order to evaluate the quality and authority of the
eported ﬁndings.
. Method
.1. Search strategy
We identiﬁed relevant papers in a comprehensive literature
earch that focused on body composition and neuromuscular
unctioning in PWS. First of all, a search for English-language publi-
ations was conducted, covering the period from January 1956, the
ear in which the ﬁrst description of the syndrome was published,
o January 2010 and using four electronic databases: Pubmed,
mbase, Cinahl, and Psycinfo. Since only Embase and Psycinfo used
he same thesaurus terms and major subheadings, the searches
ere performed separately in each database and results were com-
ined afterwards. The articles on body composition in PWS were
ound based on “body composition” as search and mesh term. The
rticles on neuromuscular functioning were found using the fol-
owing search or mesh terms: muscle(s), musculoskeletal, neural
hysiological phenomena, musculoskeletal system, musculoskele-
al development, and musculoskeletal physiological phenomena.
he search strings are listed in Appendix A. The reference lists from
elevant papers were then checked manually for supplementary
rticles not previously identiﬁed.
.2. Selection criteria
Overlapping articles were deleted. Each abstract was screened
y twoauthors (LR+MN)and included if itwas related toanoriginal
cientiﬁc article focusing on either body composition or neuromus-
ular functioning in PWS. The article was excluded if it concerned
case report, an opinion-based article, a non-systematical review,
r animal research and if there was no abstract available. Further-
ore, articles were excluded if the main subject was outside the
cope of our study. The exclusion criteria are presented in Table 1.
fter selection the full text article was screened again based on the
nclusion and exclusion criteria (Fig. 1).
.3. Evaluation of the methodological quality
The methodological quality of the included references was
valuated based on technical aspects of the study design. After
xcluding “Case reports” and “Non-systematical reviews”, we
ncludedﬁvedifferent studydesigns: RandomizedControlled Trials
RCT), Cohort Designs, Clinical Controlled Trials (CCT), Case Series
CS), and Observational Between-Subject Designs (O-BSD). Since
tandard checklistshavenotbeendeveloped for all of thesedesigns,
e therefore selected criteria from three standard checklists:
vidence-Based RichtlijnOntwikkeling (EBRO, 2005), the Physio-
herapy Evidence Database Scale (PEDro, 1999) and the Critical
ppraisal Skills Programme (CASP, 2006). We selected thirteen
elevant criteria: (1) Randomization, (2)Groupdeﬁnition, (3) Selec-
ion bias, (4) Group comparability, (5) Treatment procedure, (6)
linding, (7) Control period, (8) Study duration, (9) Measurement
rocedure, (10) Comparability of treatment, (11) Confounding
ffects, (12) Loss, and (13) Intention-to-treat. All 13 criteria were
sed to evaluate the RCT, for the CCT 12, for the Cohorts 10, for
he CS 7, and for the O-BSD 6. Two authors (LR+ LV) independently
cored each criterion. Its qualitywas determined once it was estab-
ishedwhetherornot the criterionwas reported. If the criterionwas
ell described and its quality was good, two points were assigned
or that criterion.Onepointwasassigned if the criterionwas incom-
letely described and/or its quality was doubtful. Zero points were
ssigned if the criterion was not described. The level of agreement
etween authors was determined by Cohen’s Kappa. The percent-Treatment guidance 5
Other 23
Total: 244
age of the maximum score was calculated in order to compare the
evaluations of different designs. For example: the maximum score
for an RCT was 26 points (13×2 points); if a study was evaluated
with 18 points, it scored 69%.
3. Results
3.1. Results of electronic database search
The electronic search identiﬁed 287 unique references, 38 of
which met our inclusion criteria. A ﬂow chart of the selection pro-
cedure is presented in Fig. 1. Thirty-one references were found on
body composition in PWS, of which nine were solely focused on
body composition and 22 on the effects of GH treatment on body
composition. In total 23GHeffect studieswere evaluated, since one
study contained results from an RCT as well as a CS. Seven refer-
ences were found on neuromuscular functioning in PWS. The body
composition studies (n=9) were all O-BSD. Six of the neuromuscu-
lar studies were O-BSD and there was one Cohort. In the GH effect
studies fourdesign typeswere found:RCT (n=9), CCT (n=1), Cohort
(n=1), and CS (n=12).
3.2. Body composition in PWS
3.2.1. Study characteristics
Adescription of the study characteristics is presented in Table 2.
All nine body composition references were O-BSD. Body composi-
tion was compared to normal healthy individuals (n=4) or obese
individuals (n=6). In six studies the PWSgroupwas smaller than 20
patients and in three studies the group was larger than 20 patients.
3.2.2. Methodological quality
Initially the raters reached an agreement of 87% (Cohen’s Kappa
0.77) with respect to all the criteria of the nine O-BSD studies
(9×6=54 criteria). 100% consensus was reached following con-
sultation. The quality scores for the articles reached 67 and 82%
of the maximum score. The selection procedure of patients is not
described in any of the O-BSD studies, but from the patient descrip-
tions it is possible to evaluate whether or not the patients included
are representative of PWS patients in general. Seven studies do not
report whether there was patient loss. In the three studies with
the lowest scores (67%), authors do not correct for possible differ-
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Body Composition and Muscle Structure
Total
287
Inclusion
43
Exclusion based on 
abstract
244
(Table 1)
Pubmed
277 (found)
- 0  (overlap)
277
Embase
97 (found)
-90 (overlap)
7
Cinahl
7 (found)
-7 (overlap)
0
Psycinfo
3 (found)
-0 (overlap)
3
Total Inclusion
38
Exclusion based on 
article
5
Neuromuscular
7
Body 
Composition
9
GH and Body 
Composition
23* 
RCT
9
Non-RCT
14
O-BSD
6
O-BSD
9
Body composition
31
CS
12
CCT
1
Cohort
1
Cohort
1
F al betw
C es. In
a
e
a
3
b
A
d
big. 1. Flow chart of selection procedure. GH: growth hormone, O-BSD: observation
ohort: cohort design, CS: case series. (*) The literature search revealed 22 referenc
s well as a CS.
nces in height between control subjects and PWS patients, who
re normally signiﬁcantly shorter.
.2.3. Methods used
Body composition can be measured using different techniques
ased on different principles and assumptions. Dual Energy X-Ray
bsorptiometry (DEXA) is a scanning technique that measures the
ifferential attenuation of two X-rays as they pass through the
ody. It distinguishes total Bone Mineral Content (BMC) from softeen-subject design, RCT: randomized controlled trial, CCT: clinical controlled trial,
total 23 studies were evaluated, since one reference contained results from an RCT
tissue and subsequently divides the latter into fat and lean tis-
sue. Lean tissue consists mainly of muscle tissue and is called Lean
Body Mass (LBM). Fat Free Mass (FFM) is the sum of LBM and BMC
(Uszko-Lencer et al., 2006). Another way of measuring body com-
position is based on total body water, which is called Deuterium
Dilution (DD). First total body water is measured, usually with the
double labeled water. Subsequently FFM is computed based on the
assumption that total body water represents a ﬁxed proportion of
FFM (hydration factor of 0.73) and that fat is anhydrous. Fat mass
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Table 2
Characteristics of body composition studies.
ID Study Sample Measurements Main ﬁndings Conclusions Quality
2.1 Bekx et al. (2003) Infants
- 16 PWS (m=12, 5–23
months)
- Norm values
H; W; BMI; BF%, FFM
(DEXA); BF%, FFM (DD,
n=14); TEE (DLW,
n=14); REE (IC)
PWS vs. Norm values: H ↓,
W ↓, BF% ↑, FFM ↓, TEE ↓,
TEE/FFM=, (TEE× FFM)=
Even in underweight
PWS infants BF% is
increased. Lower TEE in
infants with PWS is
caused by decreased FFM
67%
2.2 Eiholzer et al. (1999) Infants–Children
- 13 PWS under-W
(m=1, 0–4 years)
- 10 PWS over-W (m=6,
1–10 years)
- Norm values
H; W; W/H; BMI; arm-C;
Skinfolds; Leptin
(n=22); BF% (DEXA,
n=8)
PWS under-W vs. Norm:
Skinfolds =, arm-C ↓,
Leptin ↑, Skinfolds/BMI ↑
PWS over-W vs. Norm:
Skinfolds ↑, Leptin ↑,
Skinfolds/BMI ↑
Body composition in
PWS is already abnormal
in infancy, before the
onset of obesity.
82%
2.3 Hill et al. (1990) Children
- 36 PWS (m=13 years)
- 20 N-control (m=10
years)
- 11 O-control (m=10
years)
H; W; BF%, FFM (BIA);
Skinfolds; RMR (IC)
PWS vs. Norm: (W× FFM)
/= , RMR ↓, (RMR×W)
/= , (RMR× FFM) /=
PWS vs. O-control: RMR
↓, (RMR×W) /= ,
(RMR× FFM) /=
O-control vs. N-control:
RMR ↑, (RMR×W) =,
(RMR× FFM)=
Reduced FFM is not the
sole explanation for the
lower energy
expenditure seen in
patients with PWS.
67%
2.4 Van Mil et al. (2000a) Children–Adults
- 17 PWS (m=12, 7–20
years)
- 17 O-control
H; W; BMI; FFM, BF%,
ADMR (DLW); BMR (IC);
AEE
PWS vs. O-control: H=,
W=, BMI =, BF%=, FFM ↓,
BMR ↓, ADMR ↓,
BMR/FFM=, BMR/W ↓,
ADMR/W ↓, ADMR/FFM
↓
AEE is decreased in PWS
which implies decreased
physical activity.
75%
2.5 Brambilla et al. (1997) Children–Adults
- 27 PWS (m=?, 6–22
years)
- 27 N-control
- 27 O-control
W; H; BMI; W/H; BF%,
BF%-limbs, BF%-trunk,
LBM, LBM-limbs,
LBM-trunk, BMC (DEXA)
PWS vs. N-control: BF% ↑,
LBM ↓, LBM-limbs ↓,
LBM-trunk ↓, FM/LBM ↑
PWS vs. O-control: BF% ↑,
BF%-limbs ↑,
BF%-trunk=, LBM ↓,
FM/LBM ↑
O-control vs. N-control:
BF% ↑, LBM ↑, BMC ↑
PWS patients show a
peculiar body
composition, to some
extent similar to that
found in subjects
deﬁcient in growth
hormone.
75%
2.6 Van Mil et al. (2000b) Children–Adults
- 17 PWS (m=12, 7–20
years)
- 17 O-control (m=11
years)
H; W; BMI; SMR
(respiratory chamber);
BMR (IC); FFM, FFMI,
BF%, BFI (DD)
PWS vs. O-control: FFM ↓,
FFMI ↓, FM=, FMI =, SMR
↓, BMR ↓, (SMR× FFM)=,
(BMR× FFM)=
BMR and SMR are low in
patients with PWS
because of a low FFM.
75%
2.7 Van Mil et al. (2001)
Suppl. Van Mil et al.
(2000b)
Children–Adults
- 17 PWS (m=12, 7–20
years)
- 17 O-control (m=11
years)
H; W; BMI; BMR (IC);
TEE (DLW); AEE; FFM,
FFMI, BF%, BFI (DD); BF%,
BMC (DEXA)
PWS vs. O-control: FFM ↓,
FFMI ↓, FM=, FMI =,
(FMI× FFMI) =,
(FMI× FFMI) ↓
In PWS adiposity is
probably related to
abnormal GH function
and physical inactivity.
75%
2.8 Theodoro et al. (2006) Children–Adults
- 48 PWS (m=23, 10–45
years)
- 24 O-control (m=26,
11–49 years)
H; W; waist-C; hip-C;
BMI; BF%, BF%-limbs,
BF%-trunk, FFM,
FFM-limbs, FFM-trunk,
BMD (DEXA)
PWS vs. O-control: H ↓, W
↓, BMI ↓, LBM/H ↓,
LBM-limbs ↓, LBM-trunk
↓, FM/LBM ↑
Body composition in
PWS is characterized by
reduced LBM in both
limbs and trunk and
increased BF%.
75%
2.9 Schoeller et al. (1988) Children–Adults
- 10 PWS (m=?, 8–24
years)
- 10 O-control
H; W; BMI; BF%, FFM
(DD); TEE (DLW); BMR
(IC); TDEE-equation; AEE
(TEE and TDEE-equation
was used to calculate AEE)
PWS vs. O-control: H↓, W
↓, BF%=, LBM ↓, TEE ↓,
AEE/TDEE ↓
O-control: AEE=50% of
TEE (18.3 kcal/kg/day)
PWS: AEE=35% of TEE
(11.5 kcal/kg/day)
TEE is lower in PWS
patients, because of
decreased LBM and
reduced physical
activity.
67%
Population: m=mean age and age range, N-control =normal control group, O-control = obese control group. Anthropometric measurements =H=height, W=weight,
BMC=bone mineral content, BMI =body mass index, Arm-C=arm circumference, Waist-C =waist circumference, Hip-C=hip circumference. Body composition measurements:
BF%=body fat percentage, BF%-limbs=body fat percentage of limbs, BF%-trunk=body fat percentage of trunk, BFI = body fat index, FFM= fat free mass, FFMI = fat free mass
index, FFM-trunk= fat free mass of trunk, FFM-limbs= fat free mass of limbs, LBM= lean body mass, LBM-limbs= LBM of limbs, LBM-trunk= LBM of trunk, Leptin = leptin
l ture d
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s calculated by subtracting the FFM from the total body weight
Uszko-Lencer et al., 2006). Since FFM and body fat have different
lectrical properties it is alsopossible tomeasure body composition
ith Bioelectrical Impedance Analysis (BIA). In BIA two conductors
re applied to the body and resistance is measured. Conductivity
hrough FFM, which consists of water and electrolytes, is greater
han through body fat. Based on the resistance, and taking into
ccount gender, weight, and height, it is possible to calculate fat
ass and FFM (Abu et al., 1988).
Both DEXA and DD are accurate methods for measuring body
omposition (Uszko-Lencer et al., 2006). DEXA has the advantageuring activity, TDEE-equation= total daily energy expenditure based on equation,
lic rate, SMR= sleeping metabolic rate, AEE= activity related energy expenditure
beled water, DEXA=dual energy X-ray absorptiometry, IC = indirect calorimetry,
ased, ↓=decreased, + =positive, (X×Y) = correlation between X and Y.
that it not only distinguishes fat mass and FFM, but also LBM and
BMC; in addition it can deﬁne body composition in different body
regions (Brambilla et al., 1997; Theodoro et al., 2006). BIA is a less
accurate technique for measuring body composition; it is generally
assumed that it requires pathology-speciﬁc equations, which are
not available for PWS (Uszko-Lencer et al., 2006).3.2.4. Results of body composition in PWS
The results of the nine body composition articles were added to
the results of six GH studies in which PWS patients were compared
to norm values before the start of GH treatment (Table 4: 4.1, 4.2,
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similar with respect to age and gender. None of the RCTs report anL. Reus et al. / Neuroscience and Bi
.3, 4.5 and Table 5: 5.1, 5.5). All studies report an increase in fat
ass and a decrease in LBM in PWS patients compared to normal
ealthy individuals. This pattern is found in adults, children, and
ven in PWS infants who are still underweight (Table 2: 2.1, 2.2,
.3, 2.5, Table 4: 4.1, 4.2, 4.3, 4.5, and Table 5: 5.1, 5.5). In PWS
nfants, who normally have about 24% body fat, levels of 28–32%
re reported (Table 2: 2.1, Table 4: 4.1, 4.2, and Table 5: 5.1). In
WS children, levels of 36–55% are reported, while at this age body
at is normally about 18% (Table 2: 2.4, Table 4: 4.5, andTable 5: 5.5).
n both PWS infants and children LBM is 50–60% of total bodymass,
hereas in normal healthy individuals this is about 80% (Table 2:
.4, and Table 4: 4.2, 4.5). Moreover, fat distribution is different in
WS patients. Although PWS patient have the same percentage of
ody fat in comparison to individuals with simple obesity, the fat
ass in PWS patients is signiﬁcantly more increased in the limbs
Table 2: 2.5, 2.8). In contrast, LBM is decreased in all body regions
Table 2: 2.5, 2.8).
The marked increase in fat mass in PWS patients indicates an
mbalance between energy intake and energy expenditure. This
annot be solely explainedby an increased energy intake since even
hen PWS patients are underweight in infancy, before hyperpha-
ia develops, body fat is increased (Table 2: 2.1, 2.2). Even more
mportantly, energy expenditure is decreased in PWS infants, chil-
ren and adults (Table 2: 2.1, 2.3, 2.4, 2.6, 2.9, and Table 4: 4.5). In
ormal healthy adults there is a relation between body composi-
ion andenergy expenditure, LBM is found tobe themost predictive
ariable for Basal Metabolic Rate (BMR) (Cunningham, 1980). Since
MR is responsible for 70% of total energy expenditure, LBM is
he most predictive variable for energy expenditure. With respect
o energy expenditure, some authors report that decreased BMR
r decreased total energy expenditure can solely be explained by
ecreasedLBMinPWS(Table2: 2.1, 2.6),whereasothers report that
BM is not solely responsible and that PWS patients are probably
lso less active (Table 2: 2.3, 2.4, 2.9).
.3. Neuromuscular functioning in PWS
.3.1. Study characteristics
The seven references regarding neuromuscular functioning in
WS belong to four different domains of the motor system: (1)
orticospinal excitability and conductivity, (2) muscle tissue, (3)
iochemical muscle characteristics, and (4) muscle functioning. A
escription of the study characteristics is presented in Table 3. Six
-BSD studies were included and one Cohort. PWS patients were
ompared to norm values, normal control subjects, hypotonic con-
rol subjects, and/or obese control subjects. In only two studies
ore than 20 patients were included.
.3.2. Methodological quality
Initially the raters reached an agreement of 98% (Cohen’s Kappa
.96) with respect to all the criteria of the seven articles (7×6=42
riteria). 100% consensus was reached following consultation. The
uality scores for the articles reached 50–92% of the maximum
core.
.3.3. Methods used
The following methods were used to evaluate neuromuscu-
ar functioning in PWS: transcranial magnetic stimulation (TMS)
f the motor cortex and motor evoked potential (MEP) to evalu-
te corticospinal excitability and conductivity (Civardi et al., 2004);
uscle ultrasounds and muscle biopsies to evaluate muscle tissueHeckmatt et al., 1988; Sone, 1994; Aﬁﬁ and Zellweger, 1969);
evels of CoQ10, an essential coenzyme for energy synthesis, to
valuate biochemical muscle characteristics (Butler et al., 2003);
nd maximum expiratory and aspiratory pressure and isokinetic
ynamometry to assess muscle functioning of thoracic musclesioral Reviews 35 (2011) 956–969 961
and knee ﬂexor (Hakonarson et al., 1995; Capodaglio et al.,
2009).
3.3.4. Results of neuromuscular functioning in PWS
Motor cortex functioning seems to be affected in adult PWS
patients. Based on TMS and MEPs the relaxed motor threshold is
increased and intracortical facilitation is decreased, which indi-
cates hypo-excitability of the motor cortical areas (Table 3: 3.1).
Qualitative studies from muscle biopsies reveal some muscle tis-
sue abnormalities: type-2 ﬁber atrophy, type-2B ﬁber deﬁciency
and an increased amount of the immature type-2C ﬁbers (Table 3:
3.3), morphological abnormalities of contractile elements and
mitochondria (Table 3: 3.2). Additionally, type-1 ﬁber size is sig-
niﬁcantly decreased and variability is increased (Table 3: 3.3).
The muscle ultrasound scans were normal, echo intensity was not
increased which indicates that muscle tissue is not replaced by fat
or ﬁbroses in PWS patients (Table 3: 3.4). These ﬁnding were not
statistically tested. Compared tonormal controls, inmusclesof PWS
patients CoQ10 levels are decreased, indicating possible mitochon-
drial dysfunction. The normal association between CoQ10 levels
and age was also absent (Table 3: 3.5). Both studies on muscle
function report decreased muscle strength: compared to controls
muscle force in knee ﬂexors is 70% decreased (Table 3: 3.7), and
decreased muscle strength of thoracic muscles in PWS patients
leads to impaired pulmonary function (Table 3: 3.6).
3.4. Effects of GH treatment on body composition
3.4.1. Study characteristics
The literature search revealed 22 references pertaining to the
effects of GH treatment on body composition. In total 23 GH effect
studies were evaluated, since one study contained results from an
RCTaswell as aCS.Of the studies includedninewereRCTs (40%) and
of the remaining 14 studies the majority were CS. First we present
the results of the RCTs, the strongest study design for evaluating
treatment effects. The results of the 14 non-randomized GH effect
studies are presented subsequently.
3.4.2. Study characteristics of the RCTs
Adescription of the study characteristics is presented in Table 4.
GH was compared to placebo (n=2), or no GH treatment (no-GH,
n=5), and two studies examined the dose-dependent effect of GH
treatment. The control period varied between 6 (n=3), 12 (n=4)
and 24 (n=2) months. In two studies sample size was smaller than
20 patients and in seven studies sample size was larger than 20
patients. Body composition was measured using DEXA, DD, or BIA
(see Section 3.2.3)
3.4.3. Methodological quality RCTs
Initially the raters reached an agreement of 94% (Cohen’s Kappa
0.89) with respect to all the criteria of the nine RCTs (9×13=117
criteria). 100% consensus was reached following consultation. The
scoreswerebetween65%and77%of themaximumscore. The selec-
tion procedure of patients is not described in any of the RCTs, but
from the patient descriptions it is possible to evaluate whether or
not thepatients included are representative of PWSpatients in gen-
eral. Eight of the studies do not reportwhether the treatment group
and control group were similar with regard to percentage of body
fat and LBMbefore the start of treatment, although the groupswereintention-to-treat, it is therefore not possible to evaluate whether
everyone who received treatment was considered part of the trial,
andwhether they completed it or not. Since patient losswas absent
or small in the RCTs, the absence of an intention-to-treat is not likely
to result in misinterpretation.
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Table 3
Characteristics of neuromuscular studies.
ID Study Design Sample Measurements Main ﬁndings Conclusions Quality
3.1 Civardi et al.
(2004)
O-BSD Adults
- 21 PWS (m=25, 15–39
years)
- 11 N-control
Transcranial
Magnetic
Stimulation (TMS);
Motor Evoked
Potential (MEP)
PWS vs. N-control: Relaxed
Motor Threshold ↑, Central
Motor Conduction Time=,
Central Silent Period=,
F-wave size =, Intracortical
Inhibition=, Intracortical
facilitation ↓
TMS changes in PWS
patients indicate a
hypo-excitability of the
motor cortical areas.
75%
3.2 Aﬁﬁ and
Zellweger
(1969)
O-BSD Infants
- 7 PWS (m=5, 3)
- Norm values
Muscle biopsies
(Light microscopy
and Electron
microscopy)
PWS vs. norm value: muscle
structure with light
microscopy=, muscle
structure with electron
microscopy /= (Alternations
were found in contractile
elements and mitochondria)
The muscle alternations
could be compatible
with either primary
myopathy or neurogenic
atrophy, but they could
also be secondary to
early immobility and
disuse.
67%
3.3 Sone (1994) Cohort Infants
- 11 PWS (m=13, 8–34
months)
- 8 H-control (m=13,
8–27 months)
Muscle type
distribution,
Morphometric ﬁber
measurement
(muscle biopsies)
PWS vs. Norm: Type-1 size ↓,
Type-1 size variability ↑,
Type-2B deﬁcient, Type-2C
↑; Type-2 atrophy
PWS vs. H-control: Type-1
size variability ↑, Type-2
atrophy ↑
Muscle ﬁber immaturity
and abnormal muscle
ﬁber type distribution in
PWS patients may
contribute to muscle
hypotonia and
weakness.
60%
3.4 Heckmatt et al.
(1988)
O-BSD Infants
- 8 PWS (m=18 months)
- 214 H-control
- Norm values
Muscle ultrasound PWS vs. Norm values: Muscle
ultrasound=
Ultrasound scans are
normal in patients with
PWS.
50%
3.5 Butler et al.
(2003)
O-BSD Adults
- 16 PWS (m=25, 13–44
years)
- 13 O-control (m=27,
13–46 years)
- 15 N-control (m=23,
12–43 years)
H; W; LBM, BF%
(DEXA); Coenzyme
Q10 levels;
Metabolic
parameters
PWS vs. N-control: CoQ10
levels ↓, LBM ↓
N-control: (CoQ10×Age) +
PWS: (CoQ10×Age) /=
O-control: (CoQ10×Age) /=
PWS vs. O-control: CoQ10=;
LBM ↓
Plasma CoQ10 levels
were lower in subjects
with PWS.
67%
3.6 Hakonarson
et al. (1995)
O-BSD Children–Adults
- 35 PWS (4–54 years)
- Norm values
H; W; Pulmonary
function; Thoracic
muscle functioning
PWS vs. Norm: Forced
Expiratory Volume ↓ (72%),
Forced Vital Capacity ↓ (65%),
Forced Expiratory
Volume/Forced Vital
Capacity =, Total Lung
Capacity =, Residual volume
↑, Residual volume/Total
Lung Capacity ↑, Thoracic
muscle strength ↓
PWS patients have
ventilatory impairment
primarily as a result of
respiratory muscle
weakness.
92%
3.73306 Capodaglio et al.
(2009)
O-BSD Adults
- 6 PWS (m=27, 21–36
years)
- 20 O-control (m=29,
20–40 years)
- 14 N-control (m=30,
23–38 years)
H; W; BMI; muscle
strength knee ﬂexor
(Isokinetic
dynamometer)
PWS vs. O-control, N-control:
Muscle strength knee ﬂexor
and extensor ↓, Peak torque
↓, Peak torque/W ↓ (- 70%)
N-control vs. O-control: Peak
torque ↓, Peak torque/W ↑
In all: (Peak torque× speed)
Other factors than
obesity per se seem to
contribute to reduced
muscular strength in
PWS.
83%
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.4.4. Results RCTs: effect of GH treatment on body composition
All of the studies included reportedbeneﬁcial effects ofGHtreat-
ent on body composition: there is a decrease in the percentage
f body fat and an increase in LBM during treatment. For body fat
oth between-group effects (Table 4: 4.1, 4.5, 4.6, 4.9) and within-
roup effects are found (Table 4: 4.1, 4.2, 4.3, 4.4, 4.5). In children
he percentage of body fat decreases by about 20% during treat-
ent, but remains above normal (Table 4: 4.1, 4.4, 4.5). The effect
s far weaker in adults that have not been treated before, about 4%
Table 4: 4.9). Also for LBMbetween-group effects (Table 4: 4.1, 4.3,
.6) and within-group effects are reported (Table 4: 4.1, 4.2, 4.3,
.4, 4.9). In children LBM increases by about 25–40%, but it does
ot normalize (Table 4: 4.1, 4.4, 4.5). The effect is minimal in adults
hat have not been treated before, about 3% (Table 4: 4.9). Since GH
auses an increase in height, LBM should be corrected for height
n infants and children but this was only done in one study. LBM
orrected for height did not increase, but since it decreased in the
ontrol group a between-group differencewas found (Table 4: 4.3).
he dose-dependent effect studies of GH treatment demonstrate
hat a dose of >0.3mg/m2/day is necessary to keep the percentage−, (Peak torque/W× speed) −
age range, N-control =normal control group, O-control = obese control group, H-
ercentage, LBM= lean body mass, DEXA=dual energy X-ray absorptiometry. Effect
, (X×Y) = correlation between X and Y.
of body fat below baseline levels and LBM above baseline levels
(Table 4: 4.7, 4.8).
Furthermore, small effects of GH treatment on motor perfor-
mance and energy expenditure have been found. A between-group
difference regarding motor development in infants is reported
after 6 months of GH treatment. However after 12 months this
effect remains only signiﬁcant in patients who received GH treat-
ment before 18 months of life (Table 4: 4.1). In children physical
strength and agility improved (4.5) and expiratory muscle strength
improved (Table 4: 4.5, 4.6). Also in infants and children energy
expenditure increased compared to the control group (Table 4: 4.1,
4.2, 4.6).
3.4.5. Study characteristics of the non-RCTs
Adescription of the study characteristics is presented in Table 5.One CCT, one Cohort, and 12 CS were included. In the CCT GH
was compared to CoQ10 supplementation, and in the Cohort GH
was compared to no-GH treatment. In the CS body composition in
patients was measured at baseline and after a particular time of
treatment. The treatment duration differed between studies from
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Table 4
Characteristics of randomized GH effect studies.
ID Study Sample Intervention Measurements Main ﬁndings Conclusions Quality
4.1 Whitman et al.
(2004)
Infants
- 18 PWS-GH
- 12 PWS-no-GH
- Norm values
(m=16, 4–45
months)
GH vs. no-GH 6
months
H; W; W/H; BMI; GR;
LBM, BF%, BMC (DEXA);
Motor development;
Endocrine/metabolic
parameters
PWS vs. Norm: BF% ↑, LBM ↓
GH vs. n-GH: T.0: age =, H=,
W=, BF%=, LBM= ; T.6mo: GR
↑, BF% ↓, Motor dev. ↑
T.6 months vs. T.0: GH: H ↑, W
↑, BF% ↓, LBM ↑; no-GH: H=,
W ↑, BF% ↑, LBM ↓
GH has a positive
effect on growth
rate, BF%, and motor
development.
65%
4.2 Carrel et al. (2004)
Suppl. Whitman
et al. (2004)
Infants
- 15 PWS-GH
- 14 PWS-no-GH
- Norm values
(m=15, 4–37
months)
GH vs. no-GH 12
months
H; W; BMI; GR; LBM, BF%
(DD, DEXA N=14); TEE
(DLW); Motor
development;
Endocrine/metabolic
parameters
PWS vs. Norm: BF% ↑, LBM ↓,
TEE ↓
GH vs. n-GH: T.12 months: H
↑, BF% ↓, LBM ↑, TEE ↑, Motor
dev. = (Subgroup: Motor dev.
↑)
GH improves body
composition, and
accelerates motor
development.
69%
4.3 Festen et al. (2008b) Infants n/a
Children
- 25 PWS-GH
- 22 PWS-no-GH
- Norm values (m=6,
4–9 years)
GH vs. no-GH 24
months
H; W; BMI; head-C; LBM,
BF% (DEXA);
Endocrine/metabolic
parameters
Infants: n/a
Children PWS vs. Norm: W ↓,
H ↓, BMI ↑, Head-C ↓,
LBM-age ↓, LBM-height ↓,
BF% ↑
Children GH vs. no-GH: H↑,
LBM-height ↑
Children T.24 months vs. T0:
GH: H ↑, head-C ↑, LBM-age
↑, LBM-height =, BF% ↓;
no-GH: LBM-age ↓,
LBM-height ↓
GH-treatment
prevents the loss of
LBM seen in the
non-GH-treated
children.
77%
4.4 Lindgren et al.
(1998)
Children
- 15 PWS-GH
- 12 PWS-no-GH
(m=6, 3–12 years)
- 10 O-control (m=9,
5–12 years)
Observation 6
months, GH vs.
no-GH 12 months
H; W; GR; BMI; bone
age;
Endocrine/metabolic
parameters
PWS: Scoliosis; BF%, FFM,
BMC (DEXA, BIA)
PWS vs. O-control: H ↓
T0 vs. T.12 months: GH: H ↑,
GR ↑, FFM ↑, BF% ↓, BMI ↓;
no-GH: H=, GR=, FFM=,
BF%=, BMI =
GH resulted in an
increase in growth
rate, FFM and a
decrease in BMI.
73%
4.5 Carrel et al. (1999) Children
- 35 PWS-GH
- 19 PWS-no-GH
- Norm values
(m=10 years)
GH vs. no-GH 12
months
H; W; BMI; GR; Bone
age; BF%, LBM, BMC
(DEXA), REE (IC);
Scoliosis;
Strength/agility;
Thoracic muscle
strength;
Endocrine/metabolic
parameters.
PWS vs. Norm: BF% ↑, LBM ↓,
BMD=, REE ↓
GH vs. n-GH: GR ↑, BF% ↓,
LBM ↑
T0 vs. T.12 months: GH: GR ↑,
BF% ↓, LBM ↑, BMI =, Bone
age=, BMD=, Scoliosis =,
REE=, Thoracic muscle
strength ↑, Strength/agility ↑
GH caused decrease
in body fat and
increase in LBM.
69%
4.6 Haqq et al. (2003) Children
- 6 PWS group A
- 6 PWS group B
- Norm values (m=5,
4–15 years)
A: GH 6 months,
Placebo 6 months
B: Placebo 6 months,
GH 6 months
H; W; GR; Skinfolds,
arm-C; waist-C; hip-C;
BF%, LBM, FM, BMC
(DEXA), REE (IC);
Pulmonary functioning;
Behavior; Cognition;
Endocrine/metabolic
parameters.
PWS vs. Norm: H ↓,
Pulmonary function ↓,
GH vs. Placebo: GR ↑, BMI ↓,
BF% ↓, BF ↓, LBM ↑, REE ↑
T.6 months vs. T0: GH:
Pulmonary parameters ↑
GH improved body
composition and
REE.
77%
4.7 Carrel et al. (2001)
Suppl. Carrel et al.
(1999)
Children
- 14 PWS-GH-0.3
- 18 PWS-GH-1.0
- 14 PWS-GH-1.5
(m=11, 5–16 years)
GH 3 years,
GH-dosage 12
months
H; W; BMI; GR; bone
age; BF%, LBM, BMC
(DEXA), REE (IC, n=26);
Scoliosis;
Strength/agility;
Thoracic muscle
strength;
Endocrine/metabolic
parameters
T.3 years vs. T0 (12 months
GH-dosage)
GH-0.3: GR ↓, BF%=, LBM=,
Strength/agility =
GH-1.0: GR ↓, BF% ↓, LBM ↑,
Strength/agility =
GH-1.5: GR ↓, BF% ↓, LBM ↑,
Strength/agility =
All changes were dose
dependent
GH-induced changes
in growth and body
composition require
GH doses of
> 0.3mg/m2/day.
69%
4.8 Carrel et al. (2002)
Suppl. Carrel et al.
(2001)
Children
- 14 PWS-GH-0.3
- 18 PWS-GH-1.0
- 14 PWS-GH-1.5
(m=11, 5–16 years)
GH 4 years,
GH-dosage 24
months
HH; W; BMI; GR; bone
age; BF%, LBM, BMC
(DEXA), REE (IC, n=26);
Scoliosis;
Strength/agility;
Thoracic muscle
strength;
Endocrine/metabolic
parameters
T0 vs. T.4 years (24 months
GH-dosage)
GH-0.3: GR ↓, BF%=, LBM=,
Strength/agility =
GH-1.0: GR ↓, BF% ↓, LBM ↑,
Strength/agility =
GH-1.5: GR ↓, BF% ↓, LBM ↑,
Strength/agility =
All changes were dose
dependent
With GH
doses≥1.0mg/m2/day,
GH-induced changes
in body composition
can be sustained for
4 years.
69%
4.9 Höybye et al. (2003) Adults
- 9 PWS-GH
- 8 PWS-no-GH
(17–37 years)
GH vs. Placebo 6
months, GH 12
months
W; H; BMI; waist/hip;
BF%, LBM (DEXA);
Endocrine/
metabolic parameters
GH vs. n-GH:
- T.6months: BF% ↓
GH has beneﬁcial
effects on body
composition.
77%
Population:m=meanageandage range, PWS-GH=PWSGHtreatment group, PWS-no-GH=PWScontrol group,O-control = obese control group.Anthropometricmeasurements:
H=height, W=weight, GR=growth rate, BMC=bone mineral content, BMI =body mass index, Head-C=head circumference, Arm-C=arm circumference, Waist-C =waist cir-
cumference, Hip-C=hip circumference. Body composition measurements: FM= fat mass, BF%=body fat percentage, FFM= fat free mass, LBM= lean body mass, LBM-age= lean
body mass corrected for age, LBM-height = lean body mass corrected for height. Energy measurements: TEE= total energy expenditure, REE= resting energy expenditure.
Measurement methods: DD=Deuterium Dilution, DEXA=dual energy X-ray absorptiometry, IC = Indirect Calorimetry, BIA=Bioelectrical Impedance Analysis. Effect indica-
tion: = = similar, ↑= increased, ↓=decreased.
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Table 5
Characteristics of non-randomized GH effect studies.
ID Study Design Sample Interv. Measurements Main ﬁndings Conclusions Quality
5.1 Eiholzer et al.
(2004)
CCT Infants
- 11 PWS-GH (m=1
years)
- 6 PWS-Q10 (m=0.5
years)
- Norm values
GH 30 months vs.
CoQ10 12 months
H; W; LBM, BF%,
BMC (DD)
PWS vs. Norm: H ↓,
LBM-height ↓,
LBM-age ↓, BF% ↑,
BF%-age ↑
T.30 months vs. T.0:
GH: H ↑, W/H ↑,
LBM/H ↑, BF% ↑;
Q10: H= , LBM/H ↓,
BF%-age ↑
GH therapy in
infants lifts LBM
corrected for height
into the normal
range.
79%
5.2 Myers et al.
(2007)
Suppl. Carrel
et al. (2004)
CS Infants
- 14 PWS-GH
(m=15, 4–37
months)
GH 24 months H; W; W/H; BMI;
head-C; LBM, BF%,
BMC (DEXA); Motor
development.;
Cognition/language;
Endocrine/metabolic
parameters
Results T.0, T.12
months previously
reported
T.24months vs. T.12
months: LBM ↑, BF%
↑
PWS-GH vs. Typical
PWS: First words 14
months vs. 21–23
months. Walking
23.5 months vs.
24–30 months
The second year of
GH treatment in
PWS infants caused
an increase in LBM;
accumulation of
excess body fat was
reduced but not
prevented.
71%
5.3 Eiholzer et al.
(1997)
CS Children
- 9 PWS-GH
(m=5, 1–7 years)
GH 6 months H; W; W/H; GR;
Skinfolds; arm-C;
BF%, FFM (DEXA,
N=8)
T.6months vs. T.0: H
↑, GR ↑, W ↓, W/H ↓,
Skinfolds ↓, arm-C ↓,
BF% ↓, FFM ↑
GH has a positive
effect on body
composition in
patients with PWS.
71%
5.4 Davies et al.
(1998)
CS Children
- 25 PWS-GH
- Norm values
(m=7, 4–10 years)
GH 6 months H; W; GR; Skinfolds;
BF%, FFM (DD)
T.6months vs. T.0: GR
↑, BF% ↓, FFM ↑
GH treatment
resulted in an
increase in growth
rate, FFM and a
decrease in BF%.
71%
5.5 Lindgren and
Lindberg (2008)
Suppl. Lindgren
et al. (1998)
CS Children
- 22 PWS-GH
- Norm values
(m=7, 4–13 years)
GH 7 years H; W; BMI; BF%,
LBM, BF/LBM, BMC
(DEXA);
Endocrine/metabolic
parameters
PWS vs. Norm: H ↓,
BF% ↑, BMI ↑, LBM ↓
T.12months vs. T.0: H
↑, LBM ↑, BMI ↓, BF%
↓
T.7years vs. T.0
(n=17): LBM ↑,
BF%=, BF/LBM=
GH treatment
normalizes adult
height and improves
body composition.
79%
5.6 Eiholzer et al.
(1998)
CS Children
- 3
PWS-under-W-GH
(0–4 years)
- 6 PWS-over-W-GH
(3–7 years)
- 3 PWS-GH
(9–16 years)
GH 12 months H; W; W/H; BMI;
BF%, FFM, (DEXA,
N=9);
Endocrine/metabolic
parameters;
Interview physical
activity
T.12months vs. T.0:
Children under-W: H
↑, W/H ↑, Skinfolds
↓; Children-over-W:
H ↑, GR ↑, W ↓, W/H
↓, BMI ↓, BF% ↓, FFM
↑, Skinfolds ↓;
Adolescents: H ↑,
W/H ↑, BF% ↑, FFM ↑,
Skinfolds ↓
Parents reported
increased physical
activity
GH treatment in
PWS increases
growth rate, height
and muscle mass
and improves
physical
performance.
86%
5.7 de Lind van
Wijngaarden
et al. (2009)
CS Children
- 55 PWS (m=6)
GH 4 years H; W; BMI; head-C;
bone age; BF%, LBM,
(DEXA);
Endocrine/metabolic
parameters.
- BF%SDS decreased
the ﬁrst year and
then stabilized
- LBMSDS increased
the ﬁrst year,
decreased to
baseline values the
second year and
then stabilized
- After 4 years
height normalized,
BF%SDS >2 SDS,
LBMSDS < -2 SDS
GH improves body
composition over 4
years by decreasing
BF% and stabilizing
LBM.
83%
5.8 Myers et al.
(2000)
Suppl. Carrel
et al. (1999)
CS Children–Adolescents
- 35 PWS-GH
(m=10, 4–16 years)
GH 24 months H; W; BMI; GR, bone
age; BF%, LBM, BMC
(DEXA); REE (IC,
N=16), Scoliosis,
Strength/agility;
Thoracic muscle
strength (N=20)
Endocrine/metabolic
parameters.
T.12months vs. T.0:
GR ↑, BF% ↓, LBM ↑,
REE ↑,
strength/agility ↑,
Thoracic muscle
strength ↑
T.24months vs.
T.12months: GR ↑,
BF%=, LBM ↑, REE=,
strength/agility ↑,
Thoracic muscle
strength=
GH treatment
increases LBM,
decreases BF%,
improved
strength/agility, and
thoracic muscle
strength.
79%
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Table 5 (Continued)
ID Study Design Sample Interv. Measurements Main ﬁndings Conclusions Quality
5.9 Eiholzer et al.
(2000b)
Suppl. Eiholzer
et al. (1998)
CS Children–Adolescents
- 12 PWS-GH
GH 3.5 years H; W; W/H; BF%, FM,
LBM-height,
LBM-age (DEXA)
- Height normalized
after 3.5 years GH
- W/H stabilized
after 24 months GH
- FM, LBM, stabilized
after 12 months GH
- LBM adjusted for
height did not
increase
GH is not sufﬁcient
to normalize lean
body mass.
86%
5.10 Galassetti et al.
(2007)
Cohort Children–Adults
- 21 PWS-GH
- 16 PWS-no-GH
(3–38 years)
GH 0.6–6.3 years W; H; BMI; BF%, FM,
LBM, BMC (DEXA);
Food records
GH vs. no-GH: BMI ↓,
FM ↓, BF% ↑, caloric
intake ↑
There is no relation
between body
composition and
genetic subtypes.
GH improved body
composition, and
increased nutrient
intake, while these
variables were
unaffected by
genetic subtype.
66%
5.11 Bosio et al.
(1999)
CS Children–Adults
- 6 PWS-GH children
- 6 PWS-GH adults
(6–22 years)
Children: GH 12
months Adults: GH 6
months
H; W; BMI; BF%,
BF%-limbs,
BF%-trunk, LBM,
BMC (DEXA)
T.6months vs. T.0:
Children: H ↑, LBM
↑; Adults:
LBM-limbs ↑
T.12months vs.
T.6months: Children:
H=,
LBM ↑
GH might improve
ﬁnal stature and
exert a positive
inﬂuence on body
composition.
64%
5.12 Höybye et al.
(2003)
CS Adults
- 17 PWS-GH
(17–37 years)
GH 12 months W; H; BMI;
waist/hip; BF%, LBM
(DEXA);
Endocrine/metabolic
parameters
T.12 months vs. T.0:
BF% ↓, LBM ↑
GH has a positive
effect on body
composition with no
signiﬁcant
side-effects.
79%
5.13 Höybye (2007)
Suppl. Höybye
et al. (2003)
CS Adults
- 6 PWS-GH
(17–32 years)
GH 5 years W; H; BMI;
waist/hip; BF%, LBM
(DEXA);
Endocrine/metabolic
parameters
T.5years vs. T.0: LBM
↑
Over 5 years GH has
sustained favorable
effects on body
composition.
71%
5.14 Mogul et al.
(2008)
CS Adults
- 30 PWS-GH
(17–49 years)
GH 12 months W; H; BMI; waist-C;
hip-C; BF%, LBM
(DEXA);
Endocrine/metabolic
parameters
T.12months vs. T.0:
BF% ↓, LBM ↑
GH improves body
composition, and is
well tolerated with
no glucose
impairment.
86%
Design: CCT=Clinical Controlled Trial, CS =Case Series. Population: m=mean age and age range, PWS-GH=PWS GH treatment group, PWS-Q10=PWS CoQ10 treatment
group, PWS-no-GH=PWS control group. Anthropometric measurements: H=height, W=weight, GR=growth rate, BMC=bone mineral content, BMI =body mass index, Head-
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BM= lean bodymass, LBM-age= lean bodymass corrected for age, LBM-height = lea
easurement methods: DD=Deuterium Dilution, DEXA=dual energy X-ray absorpti
.5 to 7 years: 0.5 year (n=2), 1 year (n=4), 2 years (n=2) and
ore than 3 years (n=4). In only two longer study, patients were
easured repeatedly during treatment (Table 5: 5.7, 5.9). In nine
tudies sample sizewas smaller than 20 patients and in ﬁve studies
he sample size was larger than 20 patients. Body composition was
easured using DEXA or DD (see Section 3.2.3).
.4.6. Methodological quality non-RCTs
Initially the raters reached an agreement of 98% (Cohen’s
appa 0.96) with respect to all the criteria of the 14 non-RCTs
(13×7) + (1×9) + (1×11) =104). 100%consensuswas reached fol-
owing consultation. The quality scores for the articles reached 64%
nd 86% of themaximum score. The selection procedure of patients
s not described in 12 non-RCTs, but from the patient descriptions
t is possible to evaluate whether or not the patients included are
epresentative of PWS patients in general.
.4.7. Results non-RCTs: effect of GH treatment on body
omposition
All authors report positive effects for GH treatment on percent-
ge of body fat and on LBM and therefore support the ﬁndings of
he RCTs. An effect on body composition compared to baseline is
till seen after ﬁve years of GH treatment (Table 5: 5.5, 5.13). In two
tudies the effects of GH were evaluated repeatedly during several
ears of treatment. It was found that treatment effects on body
omposition stabilized after the ﬁrst year (Table 5: 5.7, 5.9). LBM
as corrected for height in only two studies with children. Height--C =hip circumference. Body composition measurements: FM= fat mass, BF%=body
ge of trunk, BF%-age=body fat percentage corrected for age, FFM= fat free mass,
mass corrected for height. Energymeasurements: REE= resting energy expenditure.
y, IC = Indirect Calorimetry. Effect indication: = = similar, ↑= increased, ↓=decreased.
corrected LBM increased in infants (Table 5: 5.1) but not in children
(Table 5: 5.9). In one study SDS for percentage of body fat and LBM
wereused, percentageof body fat decreasedandLBMremained sta-
ble (Table 5: 5.7). Effects ofGH treatment onmotorperformance are
also reported: physical strength and agility increased and expira-
torymuscle strength improved in children (Table 5: 5.8).Moreover,
non-signiﬁcant effects of GH onmotor performancewere reported.
Infants who were treated with GH spoke their ﬁrst words and
walked earlier than is usually seen in PWS (Table 5: 5.2). Parents of
children treated with GH reported increased physical activity and
performance in their children after starting GH treatment (Table 5:
5.6).
4. Discussion
4.1. Principal ﬁndings
4.1.1. Study characteristics
The sample size of the included studies was relatively small,
probably due to the low incidence of the syndrome. This is presum-
ably also the reason why the age range was sometimes quite large,
and control and follow-up periods were relatively short. The stud-
ies on body composition and GH treatment were methodologically
well performed and although overlapping outcome variables were
used, measurement techniques and age bands differed, and there-
fore a meta-analysis was not possible. It would be recommendable
to determine a standard method for evaluating body composition
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n PWS patients so that it is possible to perform meta-analysis. The
uality of the studies on neuromuscular functioning varied from
ood to moderate. Since they focused on very different aspects
f neuromuscular functioning, there was no overlap in outcome
ariables.
.1.2. Body composition in PWS
The ﬁrst goal of this literature study was to gather insight into
he severity of body composition abnormalities in PWS, its relation
o age, and its progress over time. Our study revealed ninemethod-
logically well-performed cross-sectional O-BSD reports on body
omposition in PWS. The reported ﬁndings were consistent: PWS
atients have increased fat mass and decreased LBM. This pat-
ern is characteristic of the syndrome, since it was found in adults
Brambilla et al., 1997; Schoeller et al., 1988; Theodoro et al., 2006;
an Mil et al., 2000b; Van Mil et al., 2001), children (Brambilla
t al., 1997; Eiholzer et al., 1999; Hill et al., 1990; Schoeller et al.,
988; Theodoro et al., 2006; Van Mil et al., 2000b, 2001) and even
n PWS infants that are still underweight (Bekx et al., 2003; Carrel
t al., 2004; Eiholzer et al., 2004; Sone, 1994;Whitman et al., 2004).
nsight into the severity of the abnormalities in relation to age and
ts progress over time should ideally be supported by longitudi-
al studies. We found only cross-sectional reports, which indicate
hat the relationship between fat mass and LBM becomes more
ut of balance over time. Two phenomena appear to be responsi-
le for this. First, in normal children body fat percentage is high in
nfancy and decreases over time in childhood (Butte et al., 2000;
an der Sluis et al., 2002) in contrast, in PWS children body fat is
lready increased in infancy, and increases further in childhood.
ver time this results in more than double the amount of body
at in children and adults with PWS in comparison to normal indi-
iduals. Second, in normal obesity LBM increases proportionally to
he increase in fat mass (Forbes, 1997; Forbes and Welle, 1983),
n PWS patients LBM does not increase when fat mass increases.
everal studies reported that LBM is only 50–60% of the total
ody mass in PWS patients instead of 80%, this is 20–30% lower
Carrel et al., 1999, 2004; Van Mil et al., 2000a). Since LBM con-
ists mainly of muscle mass, it can be concluded that muscle mass
s decreased by 25–37% in PWS patients ((20/80)×100%=25%,
30/80)×100%=37%). This presumably affects muscles in all body
egions, since LBM is decreased in all body regions (Brambilla
t al., 1997; Theodoro et al., 2006), and it is assumable that muscle
trength is affected. Longitudinal studies on body composition are
ecessary to conﬁrm these cross-sectional ﬁndings.
.1.3. Neuromuscular functioning in PWS
The second goal of this literature study was to systematically
ather studies on neuromuscular functioning in PWS. We only
ound seven explorative studies focusing on quite distinct subjects.
ost studies reported structural and functional muscle abnor-
alities: morphological abnormalities of contractile elements and
itochondria (Aﬁﬁ and Zellweger, 1969), type-2 muscle ﬁber atro-
hy,with type-2Bﬁber deﬁciency and increased immature type-2C
uscleﬁbers (Sone,1994)decreased type-1muscleﬁber size (Sone,
994.), decreased CoQ10 levels in muscle tissue indicating abnor-
al mitochondrial function (Butler et al., 2003), and decreased
trength of thoracic muscles and knee ﬂexor (Capodaglio et al.,
009; Hakonarson et al., 1995). Only one study reported hypo-
xcitability of the cortical motor areas (Civardi et al., 2004). Based
n these preliminary results, it can be hypothesized that the clin-
cal symptoms originate at least partly from innate cortical and/or
uscle pathology and partly from a secondary phenomenon of dis-
se. Therefore more research is necessary to study the relationship
etween the clinical symptoms, hypotonia and decreased muscle
ass and strength, and the presence of structural and functional
bnormalities in muscles and motor cortex.vioral Reviews 35 (2011) 956–969
4.1.4. Effects of GH treatment on body composition
The third goal of this literature study was to evaluate the
reported effects of GH treatment on body composition in PWS
patients. Our study revealed 9 methodologically well-performed
RCTs and 14 methodologically well-performed non-RCTs. The
reported ﬁndings were mainly consistent: GH positively inﬂuences
body composition; it decreases fat mass and increases LBM. Never-
theless some critical remarks must be made. First, in children the
effect of GH on body fat is much larger (20%) (Carrel et al., 1999;
Lindgren et al., 1998; Whitman et al., 2004), than in adults (4%)
(Höybye et al., 2003), however, even in children, body fat percent-
age does not normalize. Second, although for all studies the effect
of GH on LBM is reported to be much larger in children than in
adults, the actual effect seems to be overestimated because LBM
is usually not corrected for height, despite GH causing an increase
in growth rate. In three out of four studies in which LBM was cor-
rected no increasewas found (de Lind vanWijngaarden et al., 2009;
Eiholzer et al., 2000b; Festen et al., 2008b). Third, after the ﬁrst
treatment year there is no additional effect of GHon body composi-
tion (Eiholzer et al., 2000b), but the initial effect onbody fat andLBM
remains stable over time (Höybye, 2007; Lindgren and Lindberg,
2008). Therefore, GH seems to prevent LBM and body composition
becoming more out of balance over time, a phenomenon normally
seen in PWS. Furthermore, GH deﬁciency in PWS is probably not
the only cause of body composition abnormalities, since GH treat-
ment completely normalizes length but does not normalize body
composition (Lindgren and Lindberg, 2008). More research is nec-
essary to further evaluate the long-term effects of GH treatment on
body composition and the presumed effect on muscle mass.
4.2. This article in relation to the literature
This is the ﬁrst systematic reviewonbody composition andneu-
romuscular functioning in PWS. In fact, to our knowledge, there is
only one other systematic review on autism in PWS (Veltman et al.,
2005). Comparison can be made to some non-systematic reviews
on body composition and GH treatment in PWS (Allen and Carrel,
2000; Burman et al., 2001; Carrel and Allen, 2003). In general their
ﬁndings are in line with ours but they do not provide insights into
the severity of body composition abnormalities, its relation to age,
its progress over time, and the implications of correcting LBM for
height.We found one opinion based review inwhich it is proposed,
that decreasedmuscle strength couldbe the result of abnormalpro-
tein synthesis in muscle tissue as result of decreased GH secretion
(Lewis, 2000). In our systematic literature no evidence was found
for this suggestion.
4.3. Understanding motor problems in PWS
We performed this review to answer the question to which
extent abnormal body composition and abnormal neuromuscular
functioning may contribute to the motor problems in PWS. We
found evidence that muscle mass is decreased by about 25–37%.
It is suggested that this decrease is related to GH deﬁciency in
PWS (Burman et al., 2001; Eiholzer and Whitman, 2004; Swaab,
1997). However, also structural and functional abnormalities in
muscles are found (Aﬁﬁ and Zellweger, 1969; Butler et al., 2003;
Capodaglio et al., 2009; Hakonarson et al., 1995; Sone, 1994).
Although there is a rough linear relationship between muscle
strengthandmuscle cross-sectional area (Ikai andFukunaga, 1968),
in our opinion, decreased muscle mass cannot be the only rea-
son for decreased muscle strength in PWS patients. For example,
Capodaglio et al. (2009) reported that muscle strength in the
knee ﬂexor was 70% lower than normal and therefore much more
affected than expected based on decreased muscle mass alone.
Inactivity may also contribute to both decreased muscle mass and
obehav
m
b
n
c
H
1
i
c
B
t
m
p
t
b
t
a
t
d
m
l
1
o
l
H
o
t
e
(
I
p
2
2
b
e
e
t
d
c
c
a
2
m
2
w
c
o
a
t
p
H
a
t
o
m
i
t
i
a
2
t
s
t
s
s
fL. Reus et al. / Neuroscience and Bi
uscle strength, since PWS infants are found to be less active even
efore birth (Whittington et al., 2008). This inactivity may also
egatively inﬂuencemotor performance and development of corti-
al motor areas and the neuromuscular systems (Changeux, 1997;
adders-Algra, 2001; Hadders-Algra, 2004; Purves and Lichtman,
980). Another aspect that could contribute to motor problems
n PWS is the fact that although PWS patients need more mus-
le strength in daily activities, because of their overtime increasing
MI, the ratio between LBM and fat mass decreases overtime. In
he literature there is a strong focus on body composition abnor-
alities as result of GH deﬁciency in PWS as cause of the motor
roblems. Indeed theydo contribute to it, but cannot totally explain
hem. Research in PWS should therefore focus on other possi-
le causal factors. Another interesting ﬁnding in this respect is
hat in PWS motor performance is found to improve over time
lthough body composition becomes more out of balance over
ime. Motor problems are most striking in infancy, in which motor
evelopment is dramatically constraint by severe hypotonia and
uscle weakness, with as result that infants are almost motion-
ess, because they cannot overcome gravity (Aﬁﬁ and Zellweger,
969; Cassidy, 1984; Eiholzer et al., 2008). Especially in this period
f life motor activity is a strong stimulator for cortical and muscu-
ar development, the so called sensitive period (Changeux, 1997;
adders-Algra, 2001, 2004; Purves and Lichtman, 1980). In our
pinion it is very likely thatmotor problems in PWS are also related
o innate central nervous system defects, in the same manner as
ndocrine abnormalities are related to defects of the hypothalamus
Burman et al., 2001; Eiholzer and Whitman, 2004; Swaab, 1997).
ndeed, there are some structural brain abnormalities found in PWS
atients (Gabreëls et al., 1998; Iughetti et al., 2008; Kim et al.,
006; Miller et al., 1996, 2008; Swaab et al., 1995; Yamada et al.,
006), but only one study reports a possible relationship between
rain abnormalities andhypotonia (Yamada et al., 2006). The hypo-
xcitability of cortical motor areas in PWS patients are hypoth-
sized as of neurogenetic origin (Civardi et al., 2004), although
hese ﬁndings can also be related to disuse and problematic
evelopment.
Due to the strong dominant focus on body composition as
ontributing factor, and the beneﬁcial results from GH on body
omposition, it is thought that GH treatment could also positively
ffect muscle strength and motor performance (Carrel et al., 1999,
004; Eiholzer et al., 1998). Although beneﬁcial effects of GH treat-
ent onmotor performancehave been reported (Carrel et al., 1999,
004; Myers et al., 2000; Whitman et al., 2004), it is questionable
hether there is a direct relationship between GH treatment, mus-
le mass, muscle strength and motor performance. We are of the
pinion that patients will beneﬁt more from GH treatment when
lso participating in a training program, since it has been shown
hat also training has a positive effect on body composition in PWS
atients (Eiholzer et al., 2003; Schlumpfet al., 2006; Silverthornand
ornak, 1993) and training prevents disuse. Since GH treatment
lone does not normalize body composition it is possible that GH
reatment and training enhance one another and the combination
f the two will lead to better results for both body composition and
otor performance. Moreover, we advocate that especially young
nfants can proﬁt from early intervention focusing on skill acquisi-
ion and strength training to increase motor development, because
n the sensitive period the effect of training inﬂuences cortical
nd muscular development most (Changeux, 1997; Hadders-Algra,
001, 2004; Purves and Lichtman, 1980). To get more insight in
he relationship between the clinical signs and symptoms and the
tructural and functional impairments, training and the effect of
raining onmuscle strength,muscle tissue and corticalmotor areas
hould be monitored not only with clinical relevant outcome mea-
urements, but also with measurements focusing on structural and
unctional changes in muscles and cortex using non-invasive mus-ioral Reviews 35 (2011) 956–969 967
cle ultrasound scans (Scholten et al., 2003; Pillen et al., 2003) and
functional MRI.
4.4. General conclusions
In conclusion, the research on body composition and the effect
of GH has brought a lot of beneﬁts for patients with PWS in man-
aging the imbalance between fat mass and LBM, which in general
has a positive effect on motor performance and ﬁtness. However,
insight in the origin of severe motor problems and hypotonia in
infancy, and decreased muscle mass and strength in children, ado-
lescents, and adults with PWS is poor at this moment. We found
some preliminary ﬁndings that decreased muscle mass, hypotho-
nia, muscle weakness and motor problems in PWS are related to
impairments in the nervous and muscular system. Especially the
combination of mental retardation and psychiatric disorders, both
characteristic for PWS, point into the direction of brain pathol-
ogy. Research focused on functional and structural abnormalities
of cortical motor areas in PWS patients is therefore needed. It
seems also that the abnormalities in muscle mass and strength
are related to structural and/or functional abnormalities in mus-
cles. However, the interaction between (dis)use and the more
structural and functional abnormalities seems to be a clinical rel-
evant ﬁnding, since it has been shown that training also has
a positive effect. Future research should be focused on getting
insight in the relationship between clinical signs and symptoms,
and the structural and functional abnormalities in the motor sys-
tem.
Acknowledgements
We would like to express our thanks to A.C. Hokken-Koelega,
D.A.M. Festen, and R.F. de Lind van Wijngaarden of the Dutch
GrowthResearchFoundation, for the conversations anddiscussions
that enriched our thinking about the cause and effects in PWS.
Appendix A. Search strings
Pubmed ((((Muscle[tiab] OR Muscles[tiab]) OR (Musculoskeletal[tiab])
OR (“Body Composition”[tiab])) AND ((Prader Willi
Syndrome[mesh]) OR ((“Prader”[tiab] AND “Willi”[tiab]) AND
(“Syndrome”[tiab])))) OR (((Musculoskeletal and Neural
Physiological Phenomena[mesh]) OR (Musculoskeletal
System[mesh]) OR (Musculoskeletal Development[mesh]) OR
(Musculoskeletal Physiological Phenomena[mesh]) OR (Body
Composition[mesh])) AND ((Prader Willi Syndrome[mesh]) OR
((“Prader”[tiab] AND “Willi”[tiab]) AND (“Syndrome”[tiab])))))
Limit: English, Publication Date from 1956/1/1 to 2009/12/31
Chinahl (AB Muscle or AB Musculoskeletal or AB “Body Composition”)
and (TI Prader and TI Willi and TI Syndrome) Limit: Published
Date from 195601 to 201001; Language: English Search
modes – Boolean/Phrase
Psycinfo (Muscle or Muscles or Body Composition or
Musculoskeletal).ab. and (Prader and Willi and Syndrome).ti.
Limit 24 to (English language and year = “1956–2010”)
Embase (Muscle or Muscles or Body Composition or
Musculoskeletal).ab. and (Prader and Willi and Syndrome).ti.
Limit 24 to (English language and year = “1956–2010”)
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